IKBKB and plasma cell myeloma: Mutations at position 171 in the kinase domain of Inhibitor of κB kinase beta (IKKβ) have been identified in patients diagnosed with multiple myeloma [2], spleen marginal zone lymphoma [3] and mantle cell lymphoma [4].